Company / SG&A Expense
Intellia Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$119.8M
FY2025
5-year range
$71.1M / $125.8M
FY2021-FY2025
Trend
-4.8%
vs FY2024
Sector context
#126 of 152
Health Care
What the data says
Intellia Therapeutics, Inc.'s sg&a expense of $120M is lower than 83% of companies in the Health Care sector (FY2025). Increased from $116M to $120M over the past 2 years.
Based on SEC 10-K filings.
$120M in FY2025 with a 5-year CAGR of +22.1%.
Increased from $116M to $120M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.9%
- 5-Year CAGR
- +22.1%
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 152This company $119.8M Sector average $182.7B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.1%, indicating consistent growth.
- In FY2025, sg&a expense decreased 4.8% year-over-year.
- Ranks #126 out of 152 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $119.8M | -4.8% |
| FY2024 | $125.8M | +8.0% |
| FY2023 | $116.5M | +29.0% |
| FY2022 | $90.3M | +27.0% |
| FY2021 | $71.1M | +61.0% |
| FY2020 | $44.2M | +7.6% |
| FY2019 | $41.1M | +27.6% |
| FY2018 | $32.2M | +14.9% |
| FY2017 | $28.0M | +66.8% |
| FY2016 | $16.8M | +102.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026